ClinicalTrials.gg
RecruitingNCT07871513Updated Nov 5, 2026

A Study to Assess the Safety and Efficacy of Co-Reconstituted TrenibotulinumtoxinE and OnabotulinumtoxinA in Adult Participants With Moderate to Severe Upper Facial Lines

A Phase 2 interventional study of TrenibotulinumtoxinE and OnabotulinumtoxinA and Placebo in Upper Facial Lines and Glabellar Lines, sponsored by AbbVie. Recruiting at 21 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 5, 2026Start date movedNewly registered+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The objective of this Phase 2 study is to assess the safety and efficacy of single treatment of trenibotulinumtoxinE and onabotulibumtoxinA combination in adult participants with moderate to severe upper facial lines. The study has two parts; Part 1 evaluates treatment for glabellar lines.

02

Conditions studied

  • Upper Facial Lines
  • Glabellar Lines

Keywords

  • Upper Facial Lines
  • Glabellar Lines
  • TrenibotulinumtoxinE
  • OnabotulinumtoxinA
03

In context

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For glabellar lines (GL) indication: participant must have moderate or severe GL at maximum furrow as assessed by both the investigator and participant using the AGLSS at Screening and Baseline (Day 1) visits.
  • Participant must be in good health as per investigator's judgment based on medical history, physical examination, vital sign measurements, 12-lead (ECG) parameters, clinical laboratory evaluations, and neurological assessment.
  • In the investigator's opinion, participant must not have a condition or be in a situation that may put the participant at significant risk, may confound the study results, or may interfere significantly with the participant's participation in the study.

Exclusion criteria

Exclusion Criteria:

  • For GL Indication: Severe GL at rest as assessed by the investigator using the AGLSS at Screening or Baseline (Day 1).
  • History of immunization to any botulinum neurotoxin serotype or to any botulinum neurotoxin serotype or any other constituents of the study drug or its
  • Active infection or dermatological condition at the treatment injection sites.
  • Medical condition that may put the subject at increased medical risk with exposure to botulinum toxin, including diagnosed myasthenia gravis, Lambert-Eaton syndrome, amyotrophic lateral sclerosis, or any other condition that might interfere with neuromuscular function
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    TrenibotulinumtoxinE/OnabotulinumtoxinA Combination 1

    Participants will receive a single treatment of co-reconstituted trenibotulinumtoxinE and onabotulinumtoxinA.

    Drug: TrenibotulinumtoxinE and OnabotulinumtoxinA

  • Experimental
    TrenibotulinumtoxinE/OnabotulinumtoxinA Combination 2

    Participants will receive a single treatment of co-reconstituted trenibotulinumtoxinE and onabotulinumtoxinA.

    Drug: TrenibotulinumtoxinE and OnabotulinumtoxinA

  • Experimental
    TrenibotulinumtoxinE/OnabotulinumtoxinA Combination 3

    Participants will receive a single treatment of co-reconstituted trenibotulinumtoxinE and onabotulinumtoxinA.

    Drug: TrenibotulinumtoxinE and OnabotulinumtoxinA

  • Experimental
    TrenibotulinumtoxinE/OnabotulinumtoxinA Combination 4

    Participants will receive a single treatment of co-reconstituted trenibotulinumtoxinE and onabotulinumtoxinA.

    Drug: TrenibotulinumtoxinE and OnabotulinumtoxinA

  • Experimental
    TrenibotulinumtoxinE/OnabotulinumtoxinA Combination 5

    Participants will receive a single treatment of co-reconstituted trenibotulinumtoxinE and onabotulinumtoxinA.

    Drug: TrenibotulinumtoxinE and OnabotulinumtoxinA

  • Experimental
    TrenibotulinumtoxinE/OnabotulinumtoxinA Combination 6

    Participants will receive a single treatment of co-reconstituted trenibotulinumtoxinE and onabotulinumtoxinA.

    Drug: TrenibotulinumtoxinE and OnabotulinumtoxinA

  • Experimental
    TrenibotulinumtoxinE/OnabotulinumtoxinA Combination 7

    Participants will receive a single treatment of co-reconstituted trenibotulinumtoxinE and onabotulinumtoxinA.

    Drug: TrenibotulinumtoxinE and OnabotulinumtoxinA

  • Experimental
    TrenibotulinumtoxinE/OnabotulinumtoxinA Combination 8

    Participants will receive a single treatment of co-reconstituted trenibotulinumtoxinE and onabotulinumtoxinA.

    Drug: TrenibotulinumtoxinE and OnabotulinumtoxinA

  • Active comparator
    OnabotulinumtoxinA

    Participants will receive a single treatment of onabotulinumtoxinA.

    Drug: OnabotulinumtoxinA

  • Placebo comparator
    Placebo

    Participants will receive a single treatment of placebo.

    Drug: Placebo

Interventions

  • DrugTrenibotulinumtoxinE and OnabotulinumtoxinA

    Injection

  • DrugPlacebo

    Injection

  • Injection

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events (AEs)

    An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to Day 150

  2. Percentage of Participants Achieving None or Mild on the Investigator-Assessed Allergan Glabellar Lines Severity Scale (AGLSS)

    Achievement of None or Mild on the investigator-assessed AGLSS. The AGLSS is a validated 4-point scale (0=None through 3=Severe) used to assess glabellar line severity. A response of None or Mild indicates improvement in glabellar line severity.

    Time frame: Day 7

Secondary outcomes

  1. Percentage of Participants Achieving None or Mild on the Subject-Assessed AGLSS

    Achievement of None or Mild on the subject-assessed AGLSS. The AGLSS is a validated 4-point scale (0=None through 3=Severe) used to assess glabellar line severity. A response of None or Mild indicates improvement in glabellar line severity.

    Time frame: Day 7

  2. Duration Area Under the Curve (AUC) for Time-Averaged Response Based on Achievement of None or Mild on the Investigator-Assessed AGLSS

    Duration AUC (area under the curve) for time-averaged response based on achievement of None or Mild on the investigator-assessed AGLSS. The AGLSS is a validated 4-point scale (0=None through 3=Severe). This endpoint measures the duration of treatment effect over time.

    Time frame: Up to Day 150

  3. Onset Area Under the Curve (AUC) for Time-Averaged Response Based on Achievement of None or Mild on the Investigator-Assessed AGLSS

    Onset AUC (area under the curve) for time-averaged response based on achievement of None or Mild on the investigator-assessed AGLSS. The AGLSS is a validated 4-point scale (0=None through 3=Severe). This endpoint measures the rapidity of onset of treatment effect.

    Time frame: Up to to Day 7

07

Study locations

21 of 21 sites recruiting
  • Total Skin and Beauty Dermatology Center /ID# 284360
    Birmingham, Alabama 35205, United States
    Recruiting
  • Advanced Research Associates - Glendale /ID# 284389
    Glendale, Arizona 85308, United States
    Recruiting
  • Eye Research Foundation /ID# 284401
    Newport Beach, California 92663, United States
    Recruiting
  • Pacific Clinical Innovations /ID# 284406
    Vista, California 92083, United States
    Recruiting
  • DMR Research - Westport /ID# 286612
    Westport, Connecticut 06880, United States
    Recruiting
  • Sherber+Rad /ID# 286392
    Washington D.C., District of Columbia 20005, United States
    Recruiting
  • Atlanta Biomedical Clinical Research /ID# 284411
    Atlanta, Georgia 30331, United States
    Recruiting
  • Laser and Skin Surgery Center of Indiana /ID# 284383
    Indianapolis, Indiana 46260, United States
    Recruiting
  • Coleman Center For Cosmetic Dermatologic Surgery /ID# 286405
    Metairie, Louisiana 70006, United States
    Recruiting
  • DelRicht Research - Prytania Street - New Orleans /ID# 284416
    New Orleans, Louisiana 70115, United States
    Recruiting
  • Etre, Cosmetic Dermatology And Laser Center /ID# 284390
    New Orleans, Louisiana 70130, United States
    Recruiting
  • Maryland Dermatology Laser Skin and Vein Institute /ID# 285750
    Hunt Valley, Maryland 21030, United States
    Recruiting
  • Skincare Physicians /ID# 284415
    Chestnut Hill, Massachusetts 02467, United States
    Recruiting
  • Clarkston Dermatology /ID# 284483
    Clarkston, Michigan 48346, United States
    Recruiting
  • Wilmington Dermatology Center /ID# 284385
    Wilmington, North Carolina 28403, United States
    Recruiting
  • Private Practice - Dr. Brian S. Biesman /ID# 284417
    Nashville, Tennessee 37203, United States
    Recruiting
  • Westlake Dermatology Clinical Research Center /ID# 284374
    Austin, Texas 78746, United States
    Recruiting
  • J and S Studies /ID# 285693
    College Station, Texas 77845, United States
    Recruiting
  • Dallas Center for Dermatology and Aesthetics /ID# 284356
    Dallas, Texas 75225, United States
    Recruiting
  • Austin Institute for Clinical Research - Pflugerville /ID# 284375
    Pflugerville, Texas 78660, United States
    Recruiting
  • SkinDC /ID# 284403
    Arlington, Virginia 22209, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2026 (actual). Primary completion is estimated for Jun 2028, 20 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2026
First posted
Oct 13, 2026
StartActual
Oct 8, 2026
Primary completionEst.
Jun 2028
CompletionEst.
Jun 2028
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
20 sites added
Show 20 added (20 United States)
  • Total Skin and Beauty Dermatology Center /ID# 284360 · Birmingham, United States
  • Eye Research Foundation /ID# 284401 · Newport Beach, United States
  • Pacific Clinical Innovations /ID# 284406 · Vista, United States
  • DMR Research - Westport /ID# 286612 · Westport, United States
  • Sherber+Rad /ID# 286392 · Washington D.C., United States
  • Atlanta Biomedical Clinical Research /ID# 284411 · Atlanta, United States
  • Laser and Skin Surgery Center of Indiana /ID# 284383 · Indianapolis, United States
  • Coleman Center For Cosmetic Dermatologic Surgery /ID# 286405 · Metairie, United States
  • DelRicht Research - Prytania Street - New Orleans /ID# 284416 · New Orleans, United States
  • Etre, Cosmetic Dermatology And Laser Center /ID# 284390 · New Orleans, United States
  • Maryland Dermatology Laser Skin and Vein Institute /ID# 285750 · Hunt Valley, United States
  • Skincare Physicians /ID# 284415 · Chestnut Hill, United States
  • Clarkston Dermatology /ID# 284483 · Clarkston, United States
  • Wilmington Dermatology Center /ID# 284385 · Wilmington, United States
  • Private Practice - Dr. Brian S. Biesman /ID# 284417 · Nashville, United States
  • Westlake Dermatology Clinical Research Center /ID# 284374 · Austin, United States
  • J and S Studies /ID# 285693 · College Station, United States
  • Dallas Center for Dermatology and Aesthetics /ID# 284356 · Dallas, United States
  • Austin Institute for Clinical Research - Pflugerville /ID# 284375 · Pflugerville, United States
  • SkinDC /ID# 284403 · Arlington, United States
Nov 5, 2026
Start date
Oct 7, 2026→Oct 8, 2026 (actual)
Nov 5, 2026
Registered
First appeared on the registry
Oct 13, 2026
Show all 2 updates
  1. Nov 5, 2026
    20 sites added
    Show 20 added (20 United States)
    • Total Skin and Beauty Dermatology Center /ID# 284360 · Birmingham, United States
    • Eye Research Foundation /ID# 284401 · Newport Beach, United States
    • Pacific Clinical Innovations /ID# 284406 · Vista, United States
    • DMR Research - Westport /ID# 286612 · Westport, United States
    • Sherber+Rad /ID# 286392 · Washington D.C., United States
    • Atlanta Biomedical Clinical Research /ID# 284411 · Atlanta, United States
    • Laser and Skin Surgery Center of Indiana /ID# 284383 · Indianapolis, United States
    • Coleman Center For Cosmetic Dermatologic Surgery /ID# 286405 · Metairie, United States
    • DelRicht Research - Prytania Street - New Orleans /ID# 284416 · New Orleans, United States
    • Etre, Cosmetic Dermatology And Laser Center /ID# 284390 · New Orleans, United States
    • Maryland Dermatology Laser Skin and Vein Institute /ID# 285750 · Hunt Valley, United States
    • Skincare Physicians /ID# 284415 · Chestnut Hill, United States
    • Clarkston Dermatology /ID# 284483 · Clarkston, United States
    • Wilmington Dermatology Center /ID# 284385 · Wilmington, United States
    • Private Practice - Dr. Brian S. Biesman /ID# 284417 · Nashville, United States
    • Westlake Dermatology Clinical Research Center /ID# 284374 · Austin, United States
    • J and S Studies /ID# 285693 · College Station, United States
    • Dallas Center for Dermatology and Aesthetics /ID# 284356 · Dallas, United States
    • Austin Institute for Clinical Research - Pflugerville /ID# 284375 · Pflugerville, United States
    • SkinDC /ID# 284403 · Arlington, United States
    Start date Oct 7, 2026→Oct 8, 2026 (now actual)
    + 1 other change: verification date
  2. Oct 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07871513
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Oct 13, 2026
Start date
Oct 8, 2026
Primary completion
Jun 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Nov 5, 2026

Study contacts

ABBVIE CALL CENTER
Contact
abbvieclinicaltrials@abbvie.com
844-663-3742
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion